香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 對本公司股權架構之影響 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 轉換可換股債券 茲提述（i）本公司於2020年12月29日及2021年3月25日就發行本金總額1.5億美元2026年 到期有擔保可換股債券作出的公告（「該等公告」）及本公司於2021年1月14日就該事宜 發出的通函（「該通函」）；（ii）本公司於2021年6月10日、2022年6月10日、2023年6 月15日、2024年6月19日及2025年6月19日就轉換價調整作出的公告；（iii）本公司於 2024年2月22日就認購人部分行使可換股債券認沽期權（涉及本金總額6,000萬美元可換股 債券）作出的公告；及（iv）本公司於2025年10 ...

Group 1 - The company, Universal Medical (02666.HK), announced the issuance of its first phase of notes by its wholly-owned subsidiary, Universal Global International Financing Leasing (Tianjin) Co., Ltd., with a total issuance amount of RMB 200 million at a fixed interest rate of 2.08% [1] - The notes will mature in two years from November 11, 2025, and were issued at a price equivalent to 100% of their face value [1] - As of November 11, 2025, Universal Medical's stock closed at HKD 6.55, with a trading volume of 4.364 million shares and a turnover of HKD 28.423 million [1] Group 2 - The company has a market capitalization of HKD 12.352 billion, ranking 5th in the medical services sector [2] - Key financial metrics include a Return on Equity (ROE) of 12.39%, revenue of HKD 14.701 billion, and a net profit margin of 17.61% [2] - The company's gross profit margin stands at 34.34%, while its debt ratio is 73.38%, which is slightly lower than the industry average [2]

Core Viewpoint - The company has successfully issued its first tranche of notes in 2025, raising a total of 200 million RMB, with a fixed interest rate of 2.08% and a maturity of two years starting from November 11, 2025 [1] Group 1 - The issuance was completed by the company's wholly-owned subsidiary, Universal Global International Financing Leasing (Tianjin) Co., Ltd [1] - The notes were issued at a price equal to their face value of 100 RMB each [1] - The issuance date is November 10, 2025, marking a significant financial milestone for the company [1]

Core Viewpoint - The company, Global Medical (02666.HK), announced the issuance of domestic medium-term notes with a total principal amount of up to RMB 200 million [1] Group 1: Issuance Details - The first phase of the notes was completed on November 10, 2025, with an actual issuance amount of RMB 200 million [1] - The notes have a fixed interest rate of 2.08% and will mature in two years from November 11, 2025 [1] - The issuance price is set at RMB 100.0 per note, equivalent to 100% of the face value [1]

Core Viewpoint - The company has successfully issued its first tranche of notes for 2025, raising a total of RMB 200 million at a fixed interest rate of 2.08% [1] Group 1 - The wholly-owned subsidiary of the company, Universal Global International Financing Leasing (Tianjin) Co., Ltd., completed the issuance of the first tranche of notes on November 10, 2025 [1] - The notes have a maturity of two years, starting from November 11, 2025 [1] - The issuance price of each note is RMB 100.0, which is equivalent to the face value of the notes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 本公司全資附屬公司通用環球國際融資租賃（天津）有限公司 完成第一期境內中期票據發行 2 茲提述本公司日期為二零二五年十一月六日的公告（「該公告」），內容有關本公司的全資 附屬公司通用環球國際融資租賃（天津）有限公司擬議發行本金總額最高可達人民幣2億元的 二零二五年第一期境內中期票據（「第一期票據」）。除非文義另有所指，本公告所用詞與 該公告所界定者具有相同含義。 1 本公司欣然宣佈第一期票據已於二零二五年十一月十日在中國完成發行，實際發行金額為人 民幣 2 億元。第一期票據自二零二五年十一月十一日起計二年到期，固定利率為 2.08%，發 行價格為每一票據人民幣 100.0 元，發行價格等值於第一期票據面值的 100%。 承董事會 ...

Core Viewpoint - The company plans to issue a total principal amount of up to RMB 200 million in domestic medium-term notes to institutional investors in China, with the proceeds aimed at repaying maturing debts [1] Group 1 - The issuance will be conducted by the company's wholly-owned subsidiary, Universal Global International Financing Leasing (Tianjin) Co., Ltd [1] - The first phase of the notes will have a duration of two years and will feature a fixed interest rate [1] - The final interest rate will be determined through a book-building process at the time of subscription application [1]

Core Viewpoint - The company, Universal Medical (02666), announced that its wholly-owned subsidiary, Universal Global International Financing Leasing (Tianjin) Co., Ltd., plans to issue a maximum principal amount of RMB 200 million in the first phase of domestic medium-term notes for 2025, with the proceeds intended for debt repayment [1]. Group 1 - The total principal amount of the medium-term notes to be issued is up to RMB 200 million [1]. - The first phase of the notes will have a duration of two years and will feature a fixed interest rate [1]. - The net proceeds from the issuance will be used by the issuer to repay maturing debts [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 有關本公司的全資附屬公司 通用環球國際融資租賃（天津）有限公司 於中國發行第一期境內中期票據的公告 本公告乃由通用環球醫療集團有限公司（「本公司」）根據香港聯合交易所有限公司證券上 市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部內幕 消息條文（定義見上市規則）作出。 本公司的全資附屬公司通用環球國際融資租賃（天津）有限公司（「發行人」）於中國銀行 間市場交易商協會註冊在中華人民共和國（「中國」）發行本金總額最高達人民幣 10 億元的 境內中期票據，截至本公告日期剩餘額度為人民幣 10 億元。 發行人已決定向中國境內的機構投資者發行本金總額最高達人民幣 2 億元的二零二五年第一 期境 ...

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Universal Medical (02666.HK) by 1.8545 million shares on November 5, 2025, with a total net increase of 2.396 million shares over the last five trading days [1][2] - Over the past 20 trading days, there were 10 days of net reductions in holdings by southbound funds, totaling a decrease of 4.5485 million shares [1][2] - As of now, southbound funds hold 444.5 million shares of Universal Medical, representing 23.49% of the company's total issued ordinary shares [1][2] Group 2 - Universal Medical Group Co., Ltd. operates primarily in the healthcare sector in China, with two main divisions: financial services and healthcare services [2] - The financial services division includes direct financing leasing, sale-leaseback, insurance, operating leasing, and consulting services [2] - The healthcare services division encompasses medical health services, hospital operation management, medical equipment import and export trade, domestic trade, full-cycle equipment management, and medical digital technology services [2]